Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
0.0917
-0.0160 (-14.86%)
At close: Mar 28, 2025, 4:00 PM
0.0919
+0.0002 (0.19%)
Pre-market: Mar 31, 2025, 7:02 AM EDT
Company Description
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology.
It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Onconetix, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 18, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Ralph Schiess |
Contact Details
Address: 201 East Fifth Street, Suite 1900 Cincinnati, Ohio 45202 United States | |
| Phone | 513 620 4101 |
| Website | onconetix.gcs-web.com |
Stock Details
| Ticker Symbol | ONCO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001782107 |
| CUSIP Number | 682160106 |
| ISIN Number | US09610B1089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James R. Sapirstein M.B.A., R.Ph. | Executive Chairman |
| Karina M. Fedasz | Interim Chief Financial Officer |
| Andrew D. Skibo Ph.D. | Global Head of Biologics Operations |
| Dr. Brian Price Ph.D. | Head of Technology Strategy |
| Theodore Scott Yoho | Head of Business Development |
| Dr. Ali I. Fattom Ph.D. | Head of Science and Discovery |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13D/A | Filing |
| Feb 14, 2025 | SCHEDULE 13D/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | 424B3 | Prospectus |
| Feb 11, 2025 | EFFECT | Notice of Effectiveness |
| Feb 7, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |